Page 49 - Read Online

Zhang et al. Neuroimmunol Neuroinflammation 2020;7:109-19 I http://dx.doi.org/10.20517/2347-8659.2019.018 Page 117

normal pressure hydrocephalus. Trends Mol Med 2020;26:285-95.
16. Iliff JJ, Wang MH, Zeppenfeld DM, Venkataraman A, Plog BA, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid
exchange in the murine brain. J Neurosci 2013;33:18190-9.
17. Luciano MG, Dombrowski SM, Qvarlander S, El-Khoury S, Yang J, et al. Novel method for dynamic control of intracranial pressure. J
Neurosurg 2017;126:1629-40.
18. Xie LL, Kang HY, Xu QW, Chen MJ, Liao YH, et al. Sleep drives metabolite clearance from the adult brain. Science 2013;342:373-7.
19. Roman GC, Jackson RE, Fung SH, Zhang YJ, Verma AK. Sleep-disordered breathing and idiopathic normal-pressure hydrocephalus:
recent pathophysiological advances. Curr Neurol Neurosci Rep 2019;19:39.
20. Ju YE, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM. Obstructive sleep apnea treatment, slow wave activity, and amyloid-beta. Ann
Neurol 2019;85:291-5.
21. Gao Y, Tan L Yu JT. Tau in Alzheimer’s disease: mechanisms and therapeutic strategies. Curr Alzheimer Res 2018;15:283-300.
22. Schirinzi T, Sancesario GM, Ialongo C, Imbriani P, Madeo G, et al. A clinical and biochemical analysis in the differential diagnosis of
idiopathic normal pressure hydrocephalus. Front Neurol 2015;6:86.
23. Momjian S, Owler BK, Czosnyka Z, Czosnyka M, Pena A, et al. Pattern of white matter regional cerebral blood flow and autoregulation
in normal pressure hydrocephalus. Brain 2004;127:965-72.
24. Jeppsson A, Wikkelso C, Blennow K, Zetterberg H, Constantinescu R, et al. CSF biomarkers distinguish idiopathic normal pressure
hydrocephalus from its mimics. J Neurol Neurosurg Psychiatry 2019;90:1117-23.
25. Moriya M, Miyajima M, Nakajima M, Ogino I, Arai H. Impact of cerebrospinal fluid shunting for idiopathic normal pressure
hydrocephalus on the amyloid cascade. PLoS One 2015;10:e0119973.
26. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, et al. Alzheimer’s disease. Lancet 2016;388:505-17.
27. Blennow K, Biscetti L, Eusebi P, Parnetti L. Cerebrospinal fluid biomarkers in Alzheimer’s and Parkinson’s diseases-from
pathophysiology to clinical practice. Mov Disord 2016;31:836-47.
28. Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Sutela A, et al. Post-mortem findings in 10 patients with presumed normal-
pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol 2012;38:72-86.
29. Silverberg GD. Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both. Brain 2004;127:947-8.
30. Kudo T, Mima T, Hashimoto R, Nakao K, Morihara T, et al. Tau protein is a potential biological marker for normal pressure
hydrocephalus. Psychiatry Clin Neurosci 2000;54:199-202.
31. Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J
Neurol Neurosurg Psychiatry 2014;85:1065-75.
32. Pyykko OT, Lumela M, Rummukainen J, Nerg O, Seppala TT, et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic
normal pressure hydrocephalus. PLoS One 2014;9:e91974.
33. Miyajima M, Nakajima M, Motoi Y, Moriya M, Sugano H, et al. Leucine-rich alpha2-glycoprotein is a novel biomarker of
neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLoS One
2013;8:e74453.
34. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as
biological markers in MS. Neurology 2003;61:1720-5.
35. Jeppsson A, Höltta M, Zetterberg H, Blennow K, Wikkelsø C, et al. Amyloid mis-metabolism in idiopathic normal pressure
hydrocephalus. Fluids Barriers CNS 2016;13:13.
36. Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF
biomarkers. Neurology 2013;80:1385-92.
37. Tullberg M, Blennow K, Mansson JE, Fredman P, Tisell M, et al. Ventricular cerebrospinal fluid neurofilament protein levels decrease in
parallel with white matter pathology after shunt surgery in normal pressure hydrocephalus. Eur J Neurol 2007;14:248-54.
38. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal
pressure hydrocephalus. Neurology 1998;50:1122-7.
39. Marcus J, Honigbaum S, Shroff S, Honke K, Rosenbluth J, et al. Sulfatide is essential for the maintenance of CNS myelin and axon
structure. Glia 2006;53:372-81.
40. Miller A, Glass-Marmor L, Abraham M, Grossman I, Shapiro S, et al. Bio-markers of disease activity and response to therapy in multiple
sclerosis. Clin Neurol Neurosurg 2004;106:249-54.
41. Lamers KJB, Vos P, Verbeek MM, Rosmalen F, van Geel WJA, et al. Protein S-100B, neuron-specific enolase (NSE), myelin basic
protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull
2003;61:261-4.
42. Longatti PL, Canova G, Guida F, Carniato A, Moro M, et al. The CSF myelin basic protein: a reliable marker of actual cerebral damage in
hydrocephalus. J Neurosurg Sci 1993;37:87-90.
43. Nakajima M, Miyajima M, Ogino I, Watanabe M, Miyata H, et al. Leucine-rich alpha-2-glycoprotein is a marker for idiopathic normal
pressure hydrocephalus. Acta Neurochir (Wien) 2011;153:1339-46.
44. Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, et al. Neuroinflammation induces neurodegeneration. J Neurol
Neurosurg Spine 2016;1.
45. Tarkowski E, Tullberg M, Fredman P, Wikkelso C. Normal pressure hydrocephalus triggers intrathecal production of TNF-alpha.
Neurobiol Aging 2003;24:707-14.
46. Castaneyra-Ruiz L, Gonzalez-Marrero I, Carmona-Calero EM, Abreu-Gonzalez P, Lecuona M, et al. Cerebrospinal fluid levels of tumor